<DOC>
	<DOCNO>NCT03033836</DOCNO>
	<brief_summary>Prospective , open , single-arm trial dolutegravir-tenofovir emtricitabine lamivudine ( DTG-TDF-FTC 3TC ) antiretroviral ( ART ) naïve HIV transgender woman ( TGW ) . The primary objective pilot study determine retention care TGW treat DTG-TDF-FTC 3TC Secondary objective : - To evaluate efficacy antiretroviral regimen week 48 ; - To describe safety tolerability regimen ; - To evaluate adherence across 48 week ; - To determine patient satisfaction regimen ; - To identify individual , social contextual factor associate adherence retention .</brief_summary>
	<brief_title>Dolutegravir Plus Tenofovir/Lamivudine Emtricitabine HIV-1 Infected Transgender Women</brief_title>
	<detailed_description>The primary objective pilot study determine retention care TGW treat DTG-TDF-FTC . The primary objective assess proportion individual provide information ART use virological outcome end study : - Retention care : Proportion enrol dosed individual provide clinical information 48 week follow . - Retention treatment : Proportion enrol dosed individual receive study drug 48 week follow . Secondary objective : - To evaluate efficacy antiretroviral regimen week 48 ; - To describe safety tolerability regimen ; - To evaluate adherence across 48 week ; - To determine patient satisfaction regimen ; - To identify individual , social contextual factor associate adherence retention . The secondary objective evaluate use follow endpoint : 1 . Proportion patient HIV-1 RNA level less 50 copies/mL 48 week treatment IIT-exposed snapshot FDA algorithm ; 2 . Frequency , type severity adverse event laboratory abnormality ; 3 . Pill count , analogue visual scale adherence visit ; 4 . Changes score stigma discrimination scale , quality life , social support anxiety depression ( BERGER , WBI , DUKE , CES-D , STAI ) bsl , 4,24 , 48 week e ; .Changes score scale sexual behavior , use drug /alcohol bsl visit . f. Through association baseline individual , social contextual characteristic percentage adherence retention 48 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . HIV1 positive serology least two different serological test ( rapid test , ELISA , Western Blot ) viral load high 3,000 copies/mL . 2 . 18 year old . 3 . Selfidentified TGW 4 . ART naïve . 5 . Written inform consent provide . 1 . Genotypic resistance TDF and/or FTC per IASUSA resistance panel 2013 . 2 . Alcohol drug use might affect adherence . 3 . Concomitant use lipidlowering drug , interferon , interleukin2 , cytotoxic chemotherapy , dofetilide ( pilsicainide ) immunosuppressor , antacid drug contain Ca++ Mg++ study entry . 4 . Opportunistic infection ( CDC `` C '' category ) disease and/or clinical condition , investigator 's opinion , would compromise patient 's safety outcome study ; include malignancy cutaneous Kaposi 's sarcoma , basal cell carcinoma , noninvasive cutaneous squamous cell carcinoma , cervical intraepithelial neoplasia . 5 . Treatment follow agent within 28 day screen : radiation therapy ; cytotoxic chemotherapeutic agent ; immunomodulators alter immune response treatment HIV1 immunotherapeutic vaccine within 90 day screen exposure experimental drug experimental vaccine within either 28 day , 5 halflives test agent , twice duration biological effect test agent , whichever longer , prior first dose investigational product . 6 . Contraindication study drug ( history renal disease , lab abnormality grade 4 clinical condition prior therapy , opinion investigator , would make subject unsuitable study unable comply dose requirement ) . 7 . Anticipated need Hepatitis C virus ( HCV ) therapy study . 8 . Creatinine clearance &lt; 50 mL/min via CockroftGault method . 9 . Subjects moderate severe hepatic impairment ( Class B great ) determine ChildPugh classification .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>transgender woman</keyword>
</DOC>